Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I

04-Jan-2024 - Evotec SE and Owkin, a French-American techbio startup announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation (“I&I”). The collaboration brings together highly complementary platforms and expertise to accurately select targets, discover and ...

Evotec and Dewpoint Therapeutics enter strategic partnership in oncology

Agreement is based on a risk-sharing arrangement followed by milestone and royalty payments to Evotec based on success of overall programmes

08-Nov-2023 - Evotec SE and Dewpoint Therapeutics announced a strategic R&D collaboration to advance Dewpoint’s leading oncology pipeline programmes of condensate modifying therapeutics (“c-mods”) to Investigational New Drug Applications (“INDs”) using Evotec’s industry-leading fully integrated data-driven ...

New incubator to promote drug discovery and create new therapeutics companies in Singapore

Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch "65LAB"

06-Oct-2023 - Evotec SE announced that the Company has entered into a new BRIDGE partnership with Lightstone Ventures, ClavystBio, Leaps by Bayer, Polaris Partners, and the Polaris Innovation Fund. “65LAB”, Evotec’s first academic BRIDGE in Asia, aims to advance drug discovery and the creation of new ...

Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis

24-Mar-2023 - Evotec SE announced that the Company has received a US$ 6.6 m grant from The Bill & Melinda Gates Foundation for drug discovery in tuberculosis (“TB”). The grant is the second award from the foundation to Evotec supporting TB drug discovery, and allows the Company to progress a portfolio of TB ...

Evotec enters a drug discovery collaboration with Janssen

Milestones up to approximately € 210 m per project

14-Jun-2022 - Evotec SE announced that the Company has entered a drug discovery collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Evotec’s innovative TargetAlloMod platforms will be evaluated to discover first-in-class novel mode of action ...

Evotec receives € 7.5 m grant for development of COVID-19 therapeutic

Evotec is developing a highly potent immunomodulatory molecule that holds the potential to reduce the risk of difficult disease progression and hospitalisation

04-Jan-2022 - Evotec SE announced that the Company has been selected by the German Federal Ministry of Education and Research (“BMBF”) to receive a grant for the development of EVT075, a potential first-in-class immunomodulatory therapy against COVID 19. Evotec is one of three companies receiving a highly ...

Evotec and EQRx announce integrated drug discovery and development partnership

Biotech startup aims to deliver important new therapies to patients at more affordable prices

22-Nov-2021 - Evotec SE and EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, announced a collaboration to design, discover and develop new therapeutic options for patients. The collaboration will help accelerate ...

Evotec achieves milestone in its neurodegeneration collaboration with Bristol Myers Squibb

Evotec receive a US$ 6 m payment

05-Jan-2021 - Evotec SE announced that the Company has received a US$ 6 m payment from Bristol Myers Squibb Company within the companies’ iPSC-based neuroscience partnership. The payment follows Bristol Myers Squibb’s decision to add another drug discovery project to the partnership’s portfolio. Evotec and ...

Evotec enters partnership with Vienna start-up

Quantro exploits innovative functional-genetic and transcriptomic technologies to address “undruggable” targets

22-Jul-2020 - Evotec SE announced that the Company has entered into a comprehensive partnership with the recently established QUANTRO Therapeutics GmbH, a research-based biotech company based in Vienna, Austria, that strives to discover and develop novel therapeutics interfering with disease-causing ...

Drug discovery with artificial intelligence

Evotec participates in Exscientia's financing round

29-May-2020 - Evotec SE announced that the Company has participated in the Series C funding round of Exscientia, the Artificial Intelligence (AI)-driven drug discovery company. The funding round led by new investor Novo Holdings raised $ 60 m with the existing investors’ consortium consisting of Evotec, ...